DiCE Places Bets On Tomorrow's Small Molecules

Emerging Company Profile: New technology platform aims to apply directed evolution to identify small molecule candidates, much like large molecules like monoclonal antibodies are developed, which the Calif. start-up thinks can bring oral drugs to new fields.

Kevin Judice, CEO DiCE Molecules.
Kevin Judice, CEO of DiCE Molecules

More from Start-Ups & SMEs

More from Business